Cargando…

Pegbelfermin (BMS‐986036), PEGylated FGF21, in Patients with Obesity and Type 2 Diabetes: Results from a Randomized Phase 2 Study

OBJECTIVE: Obesity and type 2 diabetes mellitus (T2DM) are risk factors for nonalcoholic fatty liver disease, including nonalcoholic steatohepatitis. This study assessed pegbelfermin (BMS‐986036), recombinant PEGylated human fibroblast growth factor 21 (FGF21), in patients with obesity and T2DM pred...

Descripción completa

Detalles Bibliográficos
Autores principales:	Charles, Edgar D., Neuschwander‐Tetri, Brent A., Pablo Frias, Juan, Kundu, Sudeep, Luo, Yi, Tirucherai, Giridhar S., Christian, Rose
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2018
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6587787/ https://www.ncbi.nlm.nih.gov/pubmed/30520566 http://dx.doi.org/10.1002/oby.22344

Ejemplares similares

Pegbelfermin selectively reduces secondary bile acid concentrations in patients with non-alcoholic steatohepatitis
por: Luo, Yi, et al.
Publicado: (2021)

BMS‐986263 in patients with advanced hepatic fibrosis: 36‐week results from a randomized, placebo‐controlled phase 2 trial
por: Lawitz, Eric J., et al.
Publicado: (2021)

Pharmacokinetics, safety, and tolerability of BMS‐986263, a lipid nanoparticle containing HSP47 siRNA, in participants with hepatic impairment
por: Qosa, Hisham, et al.
Publicado: (2023)

Effect of pegbelfermin on NASH and fibrosis-related biomarkers and correlation with histological response in the FALCON 1 trial
por: Brown, Elizabeth A., et al.
Publicado: (2023)

Non-alcoholic fatty liver disease
por: Neuschwander-Tetri, Brent A.
Publicado: (2017)

The metabolic basis of nonalcoholic steatohepatitis
por: Chakravarthy, Manu V., et al.
Publicado: (2020)

Dapagliflozin: BMS 512148; BMS-512148
Publicado: (2012)

Two Faces of Pioglitazone: Sorting Out the Roles of its PPARγ Binding Versus Mitochondrial Pyruvate Carrier Inhibition Is Not So Simple
por: Yuan, Liyun, et al.
Publicado: (2021)

Phase 2 trial design of BMS-986278, a lysophosphatidic acid receptor 1 (LPA(1)) antagonist, in patients with idiopathic pulmonary fibrosis (IPF) or progressive fibrotic interstitial lung disease (PF-ILD)
por: Corte, Tamera J, et al.
Publicado: (2021)

A Rare Cause of Upper Gastrointestinal Bleeding: Sarcina ventriculi
por: Worrall, Emily B., et al.
Publicado: (2022)

Interactions between Bile Acids and Nuclear Receptors and Their Effects on Lipid Metabolism and Liver Diseases
por: Wang, David Q.-H., et al.
Publicado: (2012)

Crystal structures of trimeric HIV Env with entry inhibitors BMS-378806 and BMS-626529
por: Pancera, Marie, et al.
Publicado: (2017)

Barrel-muon-spectrometer: BMS
Publicado: (2005)

Barrel-muon-spectrometer: BMS
Publicado: (2005)

Barrel-muon-spectrometer: BMS
Publicado: (2005)

Barrel-muon-spectrometer: BMS
Publicado: (2005)

Barrel-muon-spectrometer: BMS
Publicado: (2005)

Barrel-muon-spectrometer: BMS
Publicado: (2005)

Barrel-muon-spectrometer: BMS
Publicado: (2005)

Inappropriate Testing for Acute Viral Hepatitis Is Common—Impact of an Intervention Using the Electronic Health Record in a Tertiary Teaching Hospital in the United States
por: Hammami, Muhammad Bader, et al.
Publicado: (2020)

FGF19 subfamily members: FGF19 and FGF21
por: Dolegowska, Katarzyna, et al.
Publicado: (2019)

Ezetimibe: Its Novel Effects on the Prevention and the Treatment of Cholesterol Gallstones and Nonalcoholic Fatty Liver Disease
por: de Bari, Ornella, et al.
Publicado: (2012)

An Inhibitor of Arginine‐Glycine‐Aspartate‐Binding Integrins Reverses Fibrosis in a Mouse Model of Nonalcoholic Steatohepatitis
por: Ulmasov, Barbara, et al.
Publicado: (2018)

Association between FGF19, FGF21 and lipocalin-2, and diabetes progression in PCOS
por: Cheng, Feifei, et al.
Publicado: (2021)

Construction of the MPI BMS Prototype Chamber
por: Bratzler, U, et al.
Publicado: (1997)

Developing a Natural History Progression Model for Duchenne Muscular Dystrophy Using the Six‐Minute Walk Test
por: Hamuro, Lora, et al.
Publicado: (2017)

FGF19 and FGF21: In NASH we trust
por: Talukdar, Saswata, et al.
Publicado: (2020)

Phase I trial of the novel taxane BMS-184476 administered in combination with carboplatin every 21 days
por: Bilenker, J H, et al.
Publicado: (2004)

Safety, pharmacokinetics and pharmacodynamics of branebrutinib (BMS‐986195), a covalent, irreversible inhibitor of Bruton's tyrosine kinase: Randomised phase I, placebo‐controlled trial in healthy participants
por: Catlett, Ian M., et al.
Publicado: (2020)

FGF21 and Cardiac Physiopathology
por: Planavila, Anna, et al.
Publicado: (2015)

BMS1 Is Mutated in Aplasia Cutis Congenita
por: Marneros, Alexander G.
Publicado: (2013)

Fundamentals of FGF19 & FGF21 Action In Vitro and In Vivo
por: Adams, Andrew C., et al.
Publicado: (2012)

FGF19 and FGF21 for the Treatment of NASH—Two Sides of the Same Coin? Differential and Overlapping Effects of FGF19 and FGF21 From Mice to Human
por: Henriksson, Emma, et al.
Publicado: (2020)

Aging is associated with increased FGF21 levels but unaltered FGF21 responsiveness in adipose tissue
por: Villarroya, Joan, et al.
Publicado: (2018)

The LXR inverse agonist SR9238 suppresses fibrosis in a model of non-alcoholic steatohepatitis
por: Griffett, Kristine, et al.
Publicado: (2015)

Fibroblast Growth Factor 21 (FGF21) in Human Cerebrospinal Fluid: Relationship With Plasma FGF21 and Body Adiposity
por: Tan, Bee K., et al.
Publicado: (2011)

FGF21 as a Stress Hormone: The Roles of FGF21 in Stress Adaptation and the Treatment of Metabolic Diseases
por: Kim, Kook Hwan, et al.
Publicado: (2014)

Role of Mitochondrial Toxicity in BMS-986094-Induced Toxicity
por: Feng, Joy Y., et al.
Publicado: (2017)

Effect of BMS-470539 on lipopolysaccharide-induced neutrophil activation
por: Lee, Seongheon, et al.
Publicado: (2020)

Head Over Hepatocytes for FGF21
por: Potthoff, Matthew J., et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_mje1lonsm1dvruf7l0pucib57b